The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia

• Published in: Cancers Vol. 15; no. 13; p. 3395
• Main Authors: Čerina, Dora, Krpina, Kristina, Jakopović, Marko, Dedić Plavetić, Natalija, Seiwerth, Fran, Tomić, Snježana, Radić, Jasna, Belac Lovasić, Ingrid, Canjko, Ivana, Boban, Marijo, Samaržija, Miroslav, Vrdoljak, Eduard
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.06.2023; MDPI
• Subjects: Biomarkers; Cancer; Cancer therapies; Clinical medicine; comprehensive genomic profiling; Genes; Genetic aspects; Genomes; Genomics; Hospitals; Kinases; Laboratories; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lung diseases; Medical personnel; Medicine; Metastases; Metastasis; Mortality; Mutation; Non-small cell lung carcinoma; NSCLC; Oncology; Patients; Pharmaceutical industry; Precision medicine; Small cell lung carcinoma; Tumors; United States; Switzerland; Germany; Croatia; NSCLC; comprehensive genomic profiling; precision medicine
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15133395

Non-small cell lung cancer (NSCLC) has become the best example of precision oncology's impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and most importantly, patients. Consequently, the implementation of the precision oncology concept in medical systems, in order to achieve optimal and proven curative effects in NSCLC, is imperative. In this study, we investigated the development, challenges, and results associated with the implementation of precision oncology in NSCLC on a national level in Croatia. We conducted a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients with metastatic lung cancer, on whose tumors specimen comprehensive genomic profiling (CGP) testing was performed during 2020 and 2021. A total of 48 patients were included in the study. CGP revealed clinically relevant genomic alterations (CRGA) in 37 patients (79%), with a median of 2 (IQR 1-3) CRGA per patient. From the panel of recommended tests, , , and were the most common alterations, detected in 16 (34%), 5 (11%), and 3 (6%) patients, respectively. CGP revealed additional targetable mutations in 29 (60%) patients who would not have been tested (and consequently, whose mutations would not have been detected) according to the existing everyday standard of practice in Croatia. The tumor mutational burden was reported as high (≥10 Muts/Mb) in 19 patients (40%). CGP analysis reported some kind of targeted therapy for 34 patients (72%). CGP revealed other potentially targetable mutations, and it also determined TMB to be high in a significant number of patients. In conclusion, when possible, CGP should be used as an upfront backbone diagnostic and treatment-oriented work-up in patients with NSCLC.